Partnership
- our MetP’s pharmaceutical products are developed for licensing to partners
- we take charge of research and development in consultation with the partner
- also, we conduct preclinical and proof-of-concept studies
Developed
for licensing
Licensing to partners
We at MetP use our unique drug delivery platform for inhouse product development. Theses products are intended to be licensed to partners. MetP takes charge of the pharmaceutical development in consultation with the customer, if requested including preclinical and proof-of-concept studies. Here you find some of our MetP's OTC and drug products for nasal application.
Ready for marketing
Nascum-Plus – significantly reducing allergic symptoms
Developed for patients with allergic rhinitis. Nascum-Plus reduces allergic nasal symptoms and secretion, and it also helps regenerating the nasal mucosa.
Phase III
Testosterone
Developed for “Replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including primary hypogonadism and hypogonadotropic hypogonadism”. There is no requirement to label the drug with the FDA-Black-Box warning.
Preclinical stage
Dopamine
Developed for the indication “Attention Deficit Hyperactivity Disorder” (ADHD). This is the first product worldwide that effectively brings genuine dopamine into the brain.
Testosterone
Developed as a testosterone combination product for patients with Multiple Sclerosis (MS). Promotes remyelination of demyelinated axons combined with an immunomodulatory as well as neuroprotective potential.
Pregnenolone
Developed for the indication “Mild Cognitive Impairment”. Potential to replace cholinesterase inhibitors as cognitive enhancers. Stimulates brain levels of acetylcholine that affect learning, memory, depression and sleep.
Progesterone
Developed for the indications “Insomnia” and “Concussion” (Mild Traumatic Brain Injury). The neuroprotective effect covers different pathways.
More products, your products.
We seek to establish strategic partnerships with pharmaceutical companies. Our part consists in carrying out the pharmaceutical development in consultation with the partner and licensing our technology, e.g. by compound, indication, area of application, country, region, et cetera.
Claudia Mattern, CSO
Udo Mattern, CEO
Phone +41-41-618 30 30
Email
Summary
One product developed by MetP Pharma AG has already been introduced into the market, namely in USA, Canada, and South Korea. There are more products in different phases of development: from just having absolved preclinical testing to being ready to commercially launched. Read more about our MetP’s nasal application technology or about our business and our story.
«Despite the progress in neurosciences and a high interest in brain delivery technologies – too few drugs have been marketed for such indications so far.»